90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years

Abstract

Radioimmunotherapy (RIT) after an induction phase with conventional chemoimmunotherapy became an attractive strategy of consolidation for patients with advanced follicular lymphoma: in particular, in many studies RIT was represented by yttrium-90-ibritumomab tiuxetan (⁹⁰Y-IT). Independently by the different front-line treatment, updates on the long-term follow-up of these studies are needed because the disease course of follicular lymphoma is characterised by multiple relapses and progressively shorter durations of response. We report updated long-term efficacy and toxicity results of a multicenter phase II study on sequential treatment with four cycles of fludarabine, mitoxantrone, and rituximab followed by ⁹⁰Y-IT as front-line therapy for untreated patients with intermediate/high-risk follicular lymphoma. With a median follow-up of 84 months, only 19/49 (38.8%) complete response patients relapsed, yielding an estimated long-term disease-free survival of 62.6%. The 7-year overall survival was 72.7%. Four (7.3%) second acute myeloid leukemia occurred, with a median time following RIT of 42 months. A relevant patients' responsiveness to subsequent therapies occurred: approximately 65% of relapsed patients obtained a good clinical response after the second-line treatment. These data represented the first evidence of a real role even in the long period of 90Y-IT after a fludarabine-containing regimen plus rituximab in the treatment of high-risk follicular lymphoma.

Consolidation with radioimmunotherapy (RIT) after the induction phase including conventional chemoimmunotherapy became an attractive strategy for patients with advanced follicular lymphoma but updates of the long-term outcomes of this approach are lacking. For this reason, we report updated long-term efficacy and toxicity results of a sequential treatment with four cycles of fludarabine, mitoxantrone, and rituximab followed by ⁹⁰Y-IT as a front-line therapy for untreated patients with intermediate/high-risk follicular lymphoma. These data represented the first evidence of a real role even in the long period of RIT after a fludarabine-containing regimen plus rituximab in the treatment of high-risk follicular lymphoma: a long-term of disease-free survival (63%) and a relevant patients' responsiveness to subsequent therapies.

from Cancer via ola Kala on Inoreader http://ift.tt/1Wl1IaH
via IFTTT